---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-034128"
form_type: "8-K"
ticker: "OPRX"
cik: "0001448431"
company_name: "OptimizeRx Corp"
filed_at: "2024-04-18T23:59:59+00:00"
generated_at: "2026-06-03T18:41:09.670843+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# OptimizeRx Q4 revenue $28.4M (+44% YoY), non-GAAP net income $4.6M, reiterates 2024 guidance of $100M revenue

## Summary
- Q4 revenue $28.4M (+44% YoY); gross profit $17.8M (63% margin).
- GAAP net loss $4.1M ($0.23/share); non-GAAP net income $4.6M ($0.26/share).
- Full year revenue $71.5M (+15%); GAAP net loss $17.6M; non-GAAP net income $4.4M.
- Adjusted EBITDA Q4 $5.8M (+50% YoY); full year $3.6M.
- Reiterates FY2024 guidance: revenue ≥$100M, Adjusted EBITDA ≥$11M.

## SEC filing metadata
- accession: 0001213900-24-034128
- form_type: 8-K
- ticker: OPRX
- cik: 0001448431
- company_name: OptimizeRx Corp
- filed_at: 2024-04-18T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1448431/000121390024034128/0001213900-24-034128-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1448431/000121390024034128/ea0204128-8k_optimizerx.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-034128
- JSON: https://secwatch.observer/filing/0001213900-24-034128.json
- Plain text: https://secwatch.observer/filing/0001213900-24-034128.txt

## Key facts
- Earnings Releases
  OptimizeRx Corp reported the full year ended December 31, 2023 results: revenue $71.5 million, net income $(17.6) million, EPS $(1.03) per basic and diluted share. Guidance reaffirmed.
  - Period: the full year ended December 31, 2023
  - Revenue: $71.5 million
  - Net income: $(17.6) million
  - EPS: $(1.03) per basic and diluted share
  - Guidance: reaffirmed
  - Result: reported results
  source text: cial Highlights ● Revenue in the fourth quarter of 2023 increased 44% to $28.4 million, from $19.7 million in the same period of 2022, with the full year revenue coming in at $71.5 million, a 15% increase when compared to the same year-ago period. ● Gross profit in the fourth quarter of 2023 increased 43% year-over-year to $17.8 million. Gross profit for the full
  evidence_url: https://www.sec.gov/Archives/edgar/data/1448431/000121390024034128/0001213900-24-034128-index.htm
- Earnings Releases
  OptimizeRx Corp reported the fourth quarter ended December 31, 2023 results: revenue $28.4 million, net income $(4.1) million, EPS $(0.23) per basic and diluted share. Guidance reaffirmed.
  - Period: the fourth quarter ended December 31, 2023
  - Revenue: $28.4 million
  - Net income: $(4.1) million
  - EPS: $(0.23) per basic and diluted share
  - Guidance: reaffirmed
  - Result: reported results
  source text: Revenue in the fourth quarter of 2023 increased 44% to $28.4 million, from $19.7 million in the same period of 2022, with the full year revenue coming in at $71.5 million, a 15% increase when compared to the same year-ago period.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1448431/000121390024034128/0001213900-24-034128-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.